SCHEMBL4704936

SCHEMBL4704936

O=C(O)Cn1c(=O)c(=O)[nH]c2ccccc21

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIA1 P42261 7/20 0.63
GRIA2 P42262 7/20 0.63
GRIA3 P42263 7/20 0.63
GRIA4 P48058 7/20 0.63
GRIN2D O15399 2/20 0.60
GRIN3B O60391 2/20 0.60
GRIN1 Q05586 2/20 0.60
GRIN2A Q12879 2/20 0.60
GRIN2B Q13224 2/20 0.60
GRIN2C Q14957 2/20 0.60
GRIN3A Q8TCU5 2/20 0.60
APEX1 P27695 1/20 0.54
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53
GRIK1 P39086 2/20 0.50
GRIK2 Q13002 2/20 0.50
GRIK3 Q13003 2/20 0.50
GRIK4 Q16099 2/20 0.50
GRIK5 Q16478 2/20 0.50
KDM4E B2RXH2 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31653996 1.00 GRIA1 (0.63) GRIA1GRIA2GRIA3GRIA4GRIN2D
SCHEMBL8539712 0.86 GRIA1 (0.62) GRIA1GRIA2GRIA3GRIA4GRIN2D
SCHEMBL2255490 0.83 MEN1 (0.62) APEX1MEN1KMT2AKDM4EGLA
SCHEMBL18180193 0.82 APEX1 (0.77) APEX1MEN1KMT2AKDM4EGLA
SCHEMBL9396483 0.82 KDM4E (0.72) GRIA1GRIA2GRIA3GRIA4GRIN2D
SCHEMBL29579885 0.81 CYP1A2 (0.69) GRIA1GRIA2GRIA3GRIA4MEN1
SCHEMBL982104 0.81 CYP1A2 (0.69) GRIA1GRIA2GRIA3GRIA4MEN1
SCHEMBL8191230 0.79 GRIA1 (0.62) GRIA1GRIA2GRIA3GRIA4GRIN2D
SCHEMBL9093471 0.79 GRIA1 (0.70) GRIA1GRIA2GRIA3GRIA4GRIN2D
SCHEMBL9093930 0.79 GRIA1 (0.62) GRIA1GRIA2GRIA3GRIA4GRIN2D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2768822-B1 DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS CHIESI FARM SPA (IT) 2017-12-06 EP disclosed
EP-2768822-B1 DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS CHIESI FARM SPA (IT) 2017-12-06 EP disclosed
US-9024027-B2 Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2015-05-05 US disclosed
US-9024027-B2 Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2015-05-05 US disclosed
US-9024027-B2 Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2015-05-05 US disclosed
EP-2768822-A2 DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2014-08-27 EP disclosed
WO-2013057013-A2 DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2013-04-25 WO disclosed
US-20130102576-A1 DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2013-04-25 US disclosed
US-20130102576-A1 DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2013-04-25 US disclosed
WO-2013057013-A2 DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2013-04-25 WO disclosed
US-5514680-A ANTICONVULSANTS WITH 5,6,7-TRISUBSTITUTED-1,4-DIHYDROQUINOXALINE-2,3-DIONE THE STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY (US) 1996-05-07 US disclosed
EP-0647137-A1 GLYCINE RECEPTOR ANTAGONISTS AND THE USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1995-04-12 EP disclosed
EP-0315959-B1 Quinoxaline compounds and their preparation and use NOVO NORDISK AS (DK) 1994-03-02 EP disclosed
WO-1994000124-A1 GLYCINE RECEPTOR ANTAGONISTS AND THE USE THEREOF WEBER ECKARD (US) 1994-01-06 WO disclosed
EP-0520024-A1 QUINOXALINE COMPOUNDS AND THEIR PREPARATION AND USE. NOVO NORDISK AS (DK) 1992-12-30 EP disclosed
US-5166155-A Neurological or psychiatric diseases NOVO NORDISK A/S (DK) 1992-11-24 US disclosed
WO-1991013878-A1 QUINOXALINE COMPOUNDS AND THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1991-09-19 WO disclosed
US-5026704-A Neuroleptic agent, quisqualate-antagonist NOVO NORDISK A/S (DK) 1991-06-25 US disclosed
US-4948794-A NEUROLEPTIC AGENTS A/S FERROSAN (DK) 1990-08-14 US disclosed
EP-0315959-A2 Quinoxaline compounds and their preparation and use NOVO NORDISK A/S (DK) 1989-05-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130102576-A1 DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS PDE4A, PDE3A, PDE4B GRIA1 3137/4885GRIA2 3941/4885GRIA3 3928/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.